Diabetes Obes Metab: The effect of cylometazole on the volume of cervical artery plaques in patients with type 2 diabetes.

!---- recently published a study in the journal Diabetes Obesity and Metabolism, researchers conducted a prospective random study to assess the efficacy of silatase, a phosphoric disterase III inhibitor, in preventing atherosclerosis progression in patients with type 2 diabetes (T2D) and compare it with aspirinThe researchers randomly divided 50 patients with T2D-combined cervical atherosclerosis plaques into 200 mg/day of cylometazole (CTZ) or 100 mg/day of aspirin (ASA) for six monthsThe main endpoint of the study was the change in plaque volume measured by 3D ultrasound of the carotid arteryThe secondary endpoint of the study was a change in the mid-layer thickness (IMT) and endothelial function of the endothelial membrane assessed by laser DopplerIn the final analysis of the study, the CTZ group included 24 patients and the ASA group included 23 patientsThe average age of men (n-20) and women (n-16) was 62.2 years and 59.1 years, respectivelyThe total plaque volume of the CTZ group decreased slightly (from 183.8 to 52.5 to 181.5 to 54.0mm3, P to 0.567), but significantly increased in the ASA group (from 112.9 to 21.2 to 128.5 to 23.3mm3, P-0.043)A significant reduction in the maximum IMT was observed only in the CTZ group (right: from 2.19 to 1.96 to 1.96 to 0.12mm; left: from 2.02 to 0.20 to 1.72 to 0.19mm)HDL-cholesterol levels were elevated in the CTZ group, while triglycerides and liver enzyme levels decreasedThus, compared with aspirin, silothazole treatment for 6 months significantly reduced the progression of cervical artery plaque in T2D patients